---
title: "Psilocybin (COMP360) in Treatment-resistant depression: COMP004"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: COMP004. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 36 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence/comp004"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: COMP004

<a id="heading-3.1.4"></a>

## 3.1.4 COMP004

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Registered study purpose

> “The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).”

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.1-2"></a>

#### Published study aim

> “Here, we report findings from COMP 004, a 52-week observational follow-up of patients from COMP 001 and COMP 003, a small open-label study of the coadministration of 25 mg COMP360 with continuing antidepressant treatment.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.1-3"></a>

#### Role in the development program

> “The outcomes of the long-term follow-up study informed the design of our Phase 3 registrational program, including investigating whether a second administration of COMP360 may achieve improved durability, response and remission outcomes.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Study dates and identifiers

| Item | Registry record |
| --- | --- |
| Other study ID | “COMP004” |
| Study start (actual) | “2020-07-20” |
| Primary completion (actual) | “2022-08-11” |
| Study completion (actual) | “2022-08-11” |
| Last update posted | “2022-09-22” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.2-2"></a>

#### Sites

> “This study has 8 locations”

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.2-3"></a>

#### Data collection period

> “Data were collected from July 2020 to July 2022.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.2-4"></a>

#### Publication

> “In March 2025, the results from our observational, 52-week follow-up study (COMP004) of 66 participants who took part in our Phase 2b trial were published in the Journal of Clinical Psychiatry.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Registered design

| Item | Registry record |
| --- | --- |
| Study type | “Observational” |
| Observational model | “Ecologic or Community” |
| Time perspective | “Prospective” |
| Official title | “Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.3-2"></a>

#### Follow-up structure and duration

> “In this present study (COMP 004), the aim is to follow up participants from COMP 001 and COMP 003 in a long-term follow up study, with both remote and digital assessments”
> “Patients previously treated in COMP001 will be followed for approximately 40 weeks and patients previosuly treated in COMP003 will be followed for approximately 49 weeks giving a total follow up period of 52 weeks from psilocybin dosing.”

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Registered eligibility criteria

| Criterion | Quoted registry text |
| --- | --- |
| Consent | “Signed ICF” |
| Prior study completion | “Each participant having completed the final study visit of either COMP 001 or COMP 003” |
| Assessment capacity | “Ability to complete all protocol required assessment tools (including having access to the internet in order to complete the digital assessments) without any assistance or alteration to the copyrighted assessments, and to comply with all study visits” |
| Exclusion | “Subject has any condition, for which in the opinion of the investigator, participation would not be in the interest of the subject eg participation could compromise the wellbeing of the participant or prevent, limit, or confound the protocol-specified assessments” |
| Study population | “TRD patients who completed COMP001 or COMP003” |
| Ages eligible | “18 Years to 55 Years” |
| Sampling method | “Probability Sample” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Interventions received in the parent studies

> “to explore the long term efficacy and safety of the three different doses of psilocybin (1 mg, 10 mg, and 25 mg) administered to patients with TRD as a monotherapy in COMP 001 and 25 mg psilocybin administered as an adjunct to an SSRI in COMP 003”

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.5-2"></a>

#### No study drug administered during follow-up

> “Three participants reported experiencing a treatment emergent serious adverse event post-enrollment to COMP004, occurring more than 6 months after a single dose administration and all deemed unrelated to study drug.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Time to Depressive Event as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary endpoint definition

> “The primary efficacy endpoint was time to a prespecified depressive event over the 52 weeks following COMP360 administration in COMP 001 participants, presented as Kaplan-Meier estimates.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

> “The primary endpoint of this COMP004 study was the median time to a new depressive event.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.6.1-2"></a>

##### Registered outcome measures

| Outcome | Measure description | Time frame |
| --- | --- | --- |
| “Long-term efficacy of psilocybin” | “Use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS)” | “up to 52 weeks” |
| “Response, sustained response, remission and change in depression severity” | “Montgomery Asberg Depression Rating Scale (MADRS)” | “Up to 52 weeks” |
| “Psychosocial functioning and to predict durability of response to antidepressant treatment” | “Work and Social Adjustment Scale (WSAS) score change from Baseline of the prior study” | “up to 52 weeks” |
| “Functional impairment in work/school, social life, and family life.” | “Sheehan Disability Scale (SDS) score change from Baseline of the prior study” | “Up to 52 weeks” |
| “Safety of Psilocybin” | “Incidence and severity of Adverse Events (AEs) and Seroius Adverse Events (SAEs)” | “Up to 52 weeks” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.6.1-3"></a>

##### Regulatory expectations for durability after a single psychedelic dose

> “Therefore, sponsors should plan to evaluate the durability of response for their drug product and the safety and efficacy of repeat dosing.”
> “Sponsors should continue to follow subjects beyond the Week 12 endpoint to monitor for symptom recurrence or, potentially, the need for repeat dosing.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

> “Endurance of effect needs to be demonstrated.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.4.6.1-4"></a>

##### Time to relapse in regulatory maintenance designs

> “Because depression usually is a cyclical disease, maintenance studies of conventional”
> “antidepressants are actually assessments of the ability of the drug to reduce the rate of recurrence”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

> “Due to the character of the disorder, longer trials are necessary to demonstrate that the acute effect is maintained during an episode (relapse prevention). For this, a randomised withdrawal study is the preferred design.”
> “The duration of 6 months is not strictly necessary when a time to event approach is chosen.”
> “In randomised withdrawal trials, efficacy usually is expressed as rate of patients worsening (relapsing) and/or time to this event.”
> “Worsening or relapse has to be defined in the protocol. Usually, a clinically relevant increase in symptoms scored on a validated rating scale is used.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-3.1.4.6.1-5"></a>

##### Time to relapse as the primary endpoint in a treatment-resistant depression trial

> “Cumulative distribution of time to relapse during the maintenance phase among patients who achieved stable remission (primary efficacy end point) and those who achieved stable response without remission (secondary end point) was estimated by the Kaplan-Meier method.”
> “Relapse was defined as a MADRS total score of 22 or higher for 2 consecutive assessments separated by 5 to 15 days or hospitalization for worsening depression, suicide attempt, suicide prevention or completed suicide, or another clinically relevant event suggestive of relapse (assessed by a relapse adjudication committee).”

Source: [Daly et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6551577/)

<a id="topic-3.1.4.6.1-6"></a>

##### Clinical relevance of time-to-event endpoints in psychiatric conditions

> “The actual outcome in survival analysis is ‘time to event’, yet, in the mental health field, there has been little consideration of whether a temporary delay to relapse is clinically relevant in a condition that can last for decades.”
> “They inevitably lead to differences in time to relapse, even when there is little or no difference in the cumulative risk of relapse at final follow-up.”

Source: [Moncrieff et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9340015/)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Actual enrollment: registry record

| Enrollment type | Participants |
| --- | --- |
| Actual | “66” |

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957)

<a id="topic-3.1.4.7.1-2"></a>

##### Participants by parent-study arm: company statement

> “Of the 66 participants, 22 participants were in the 25mg group, 19 participants were in the 10mg group, 17 participants were in the 1mg group and 8 participants were in the 25mg plus SSRI group.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.7.1-3"></a>

##### Participants analyzed for the primary endpoint

> “The pre-specified primary analysis was of the median time for such an event for all participants in our Phase 2b trial, not only those who enrolled in the COMP004 study.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.7.1-4"></a>

##### Planned enrollment

No evidence found.

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Post hoc analysis set: participants who entered COMP004

> “A post hoc analysis included only participants that entered COMP 004.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

> “A post hoc analysis of the 58 participants who enrolled in the COMP004 from our Phase 2b trial revealed a substantial difference in median time to depressive event for those in the 25 mg group compared to the 10mg and 1mg groups”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Participants entering follow-up

> “Sixty-six participants entered COMP 004 (COMP 001, n = 58 [25 mg group n = 22, 10 mg group n = 19, 1 mg group n = 17]; COMP 003, n = 8).”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Antidepressant use at entry

> “At COMP 004 entry, the 1 mg group had the highest number of participants on antidepressant medication (n = 10; 10 mg, n = 9; 25 mg, n = 6) and generally initiated treatment earlier.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Median time to depressive event: published analysis

> “For all COMP 001 patients (n = 233), median time to depressive event was greater for the 25 mg group (92 days) compared to the 10 mg (83 days) and 1 mg (62 days) groups, with the majority of participants having had a depressive event by Week 12 (25 mg n = 37/75, 10 mg n = 38/79, 1 mg n = 44/75).”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.8.3-2"></a>

##### Median time to depressive event: annual report figure for the 10 mg group

> “The median time to a new depressive event was 92 days for the COMP360 25mg group compared to 86 days for the 10mg group and 62 days for the 1mg group.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.8.3-3"></a>

##### Median time to depressive event: post hoc analysis of enrolled participants

> “The post hoc supplementary analysis of those who enrolled in COMP 004 from COMP 001 exhibited the difference between groups more strikingly (25 mg, 189 days; 10 mg, 43 days; 1 mg, 21 days); however, only 10 participants experienced a depressive event post-COMP 004 enrollment (25 mg n = 6, 10 mg n = 3, 1 mg n = 1) from COMP 001 and none from COMP 003.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.8.3-4"></a>

##### Median time to depressive event: quarterly results statement

> “Recent 52-week data from an observational follow-up study published on COMP360 demonstrated a durable treatment response and a median time to depressive event of 92 days (n=252) on a single 25mg administration and 189 days (n=58) for the 25mg subgroup that continued into the COMP004 long-term extension”

Source: [COMPASS Pathways first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000162828025023427/q12025pressrelease.htm)

<a id="topic-3.1.4.8.3-5"></a>

##### New treatment for depression during follow-up

> “In addition, a lower proportion of participants started new treatments for depression in the 25mg”
> “and 10mg arm compared to the 1mg arm.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.4.8.3-6"></a>

##### Authors' conclusion

> “Over 52 weeks, a single administration of 25 mg psilocybin suggested longer maintenance of antidepressant effect than both 1 mg and 10 mg.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

Additional sources: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Adverse events after entry into follow-up

> “Few AEs were reported post-entry into COMP 004, with 1 AE of mild suicidal ideation in the 1 mg group deemed possibly related to study drug.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.8.5-2"></a>

##### Serious, ongoing, and suicidality adverse events: company statement

> “With respect to adverse events, twenty-seven or 40.9% of participants had an adverse event that was ongoing as of, or started, after week 12.”
> “Suicidality was recorded as an adverse event across all arms with two in each of the 25mg group and the 10mg group, and one in the 1mg group.”
> “COMP360 was generally well tolerated.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary: observational design, selected subgroup, few events, post hoc analysis

COMP004 was an observational follow-up that enrolled 66 participants who had completed COMP001 or COMP003, 58 of them from COMP001. The prespecified primary analysis covered all COMP001 participants, and the analysis restricted to enrolled participants was post hoc and based on 10 depressive events after enrollment. At entry, more participants in the 1 mg group were taking antidepressant medication (10, compared with 9 in the 10 mg and 6 in the 25 mg group). The published and Form 10-K medians for the 10 mg group differ (83 and 86 days). The authors state that larger long-term studies are required, and FDA guidance describes blinded long-term follow-up with prespecified retreatment criteria as the most informative design.

Source: [ClinicalTrials.gov NCT04519957](https://clinicaltrials.gov/study/NCT04519957); [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.4.9-2"></a>

#### Authors' stated limitations: few events and need for larger studies

> “Larger long-term studies are required to confirm these findings and provide clarity on the longer-term effects of psilocybin.”

Source: [Goodwin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40047545/)

<a id="topic-3.1.4.9-3"></a>

#### Unblinded observational follow-up

> “The most informative clinical trial design would incorporate blinded long-term follow-up (typically 12 months) with prespecified criteria for retreatment.”
> “These criteria should take into account symptom ratings as well as whether the participant seeks additional treatment outside the study.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.4.9-4"></a>

#### Limited evidence on durability and retreatment

> “The experience and the available information on the sustainability of the action and the long-term effects, both desirable and undesirable of psychedelics and the efficacy of re-treatment are very limited.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
